Abbott Xinlay review
Executive Summary
Abbott's selective endothelin-A receptor antagonist Xinlay to get review for treatment of metastatic hormone-refractory prostate cancer by the Oncologic Drugs Advisory Committee on Sept. 13. The committee review comes a month before the Oct. 14 estimated user fee action date for the Xinlay NDA...